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StirringAbstract The synthesis and pharmacological activity of N0-[(1Z)-(substituted aromatic) methyli-
dene] pyridine-4-carbohydrazides (3a–k) and N-[3-chloro-2-(substituted aromatic)-4-oxoazetidin-1-
yl]pyridine-4-carboxamides (5a–k) are described. Synthesis of 2-azetidinones was performed by novel
methods of stirring and sonication involving the cyclocondensation of the appropriate Schiff’s bases
(3a–k) with chloroacetyl chloride, followed by the addition of triethyl amine in the presence of
molecular sieves. The compounds were investigated for their antidepressant activity, compounds
N0-[(1Z)-(2,5-dimethoxyphenyl)methylidene]pyridine-4-carbohydrazide (3k) and N-[3-chloro-2-
(2,5-dimethoxyphenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide (5k) with 2,5-dimethoxy substi-
tution on the aryl ring exhibited the highest antidepressant activity. In the elevated plus maze test
and passive avoidance test in mice for the evaluation of nootropic activity N0-[(1Z)-(4-nitro-
phenyl)methylidene]pyridine-4-carbohydrazide (3d) and N-[3-chloro-2-(4-nitrophenyl)-4-oxoazeti-
din-1-yl]pyridine-4-carboxamide (5d) with para nitro substitution on the aryl ring exhibited the
highest activity. All synthesised Schiff’s bases and azetidinone analogues exhibited antidepressant
and nootropic activities in a dose dependant manner. The results conﬁrmed the fact that the 2-aze-
tidinone skeleton has potential as a CNS active agent and can be explored for the development of
more potent and safe CNS active agents for therapeutic use.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
2-Azetidinones, commonly known as b-lactams, are well-
known heterocyclic compounds among the organic and medic-
inal chemists. The activity of the known antibiotics such as pen-
icillins, cephalosporins and carbapenems are attributed to the
presence of 2-azetidinone ring in them. The broad and potent
activity of 2-azetidinones has established them as one of the bio-
logically important scaffold (Risi et al., 1999). Recently, other
S80 A.B. Thomas et al.biological activities besides the antibacterial activity have been
reported in compounds containing the 2-azetidinone ring
(Singh et al., 2007). The recent discoveries of some 1,3,4-trisub-
stituted-b-lactams as new potent cholesterol absorption inhibi-
tors, human cytomegalovirus protease inhibitors and thrombin
inhibitors justiﬁed a renewed interest in these compounds.
Furthermore, interest in chemistry, synthesis and biology of
2-azetidinone pharmacophore continues to be researched due
to their wide range of biological properties, such as antibacterial
(Chavan and Pai, 2007; Desai and Desai, 2006; Singh and
Mmolotsi, 2005), antihyperglycemic (Leach and Deirdre,
2001), antihyperlipidemic (Wu et al., 1999; Xu, 2007), CNS
activity (Goelab et al., 2005), tryptase inhibitory (Bisacchi
and Slusarchyk, 2004), human leucocyte elastase inhibitory
(Hagmannt et al., 1991), anti-inﬂammatory (Kumar and
Rajput, 2009), vasopressin v1a antagonist (Guillon and
Koppel, 2004), and anticancer activity (Banik et al., 2005;
Banik et al., 2003).
2-Azetidinones have not been reported so far as CNS active
agents; however, the presence of this moiety in a variety of het-
erocyclic compounds has been reported to increase the CNS
activity of the parent structure. Reports of compounds con-
taining a quinazoline ring at N-1 position of 2-azetidinone ring
have resulted in compounds with potent activity against
oxtremorine induced tremors and as antiparkinson agents.
The active compounds have phenyl, 2-chlorophenyl and 2-fur-
yl groups at C-4 position of azetidinone ring (Srivastva et al.,
1987). The synthesis of benzopyran-2-one substituted 2-azetid-
inone derivatives at N-1 position of ring with signiﬁcant CNS
depressant has been reported (Kulkarni et al., 1996). Many
researchers have also reported the substitution of heterocyclic
rings such as carbazole ring at N-1 position of the 2-azetidi-
none nucleus (Srivastava et al., 1999) and 1,2,4-triazole deriv-
ative of 2-azetidinones (Srivastava et al., 2002) resulting in
compounds with anticonvulsant properties. The presence of
halogens in the biologically active molecules has shown to play
a crucial role in their pharmacological properties. Spiroazetid-
inones derived from 3-(N-substituted) imino-1-methylindol-2-
ones have also been reported as anticonvulsants (Singh et al.,
1994). Recently various 2-azetidinones were synthesised which
were further evaluated for their CNS modulating activities
using the computer software PASS (Prediction of activity spec-
tra for substances) (Goel et al., 2005). Lately azetidinone deriv-
atives have also been reported for the treatment of Alzheimers
disease (Davis et al., 2003). It is postulated that azetidinones
may exert this effect due to their ability to regulate the produc-
tion of amyloid-b-peptides (Puglielli et al., 2001).
The Staudinger’s ketene-imine cycloaddition reaction
[2+2] is the most common method for the synthesis of azetid-
inones (Staudinger, 1907) and has been reviewed till date by
several researchers. The reactions are carried out thermally
(Alcaide et al., 2000) or photochemically (Griesbeck and
Heckroth, 2002) using acid chlorides in the presence of
triethylamine or a-diazoketones as ketene precursors. However
the conventional methods reported for the synthesis of
2-azetidinones require longer reaction times (12–16 h reﬂux)
Barrett et al., 2000; Escalante et al., 2001 at very low
temperature (70 to 90 C) (Alcaide et al., 2001; Banik
and Becker, 2000) with low yields (less than 70%) Penfold
et al., 2000. The reactions also involve the use of a Dean-stark
water separator for the removal of water from the reaction.
The previous decade has also seen the use of microwaveradiation in the synthesis of azetidinones. However, the
reported microwave methods also required an inert atmo-
sphere of nitrogen gas to enable the completion of the reaction
(Bose et al., 1996, 1995).
On the basis of the above ﬁndings and considering the need
for the development of potent CNS active agents, we were
stimulated to explore new simpliﬁed 2-azetidinone analogues
for their antidepressant and nootropic activities. Here, in this
paper, we are reporting the synthesis of N-[3-chloro-2-(substi-
tuted aromatic)-4-oxoazetidin-1-yl]pyridine-4-carboxamide
analogues by our previously reported green route methods of
stirring and sonication and their screening for antidepressant
and nootropic activities.2. Experimental
2.1. General considerations
All research chemicals were purchased from Across organics
(NY, USA), Sigma-Aldrich (St. Loius, Missiouri, USA) and
used as such for the reactions. Melting points (mp) were deter-
mined on a Veego melting point apparatus (VMP PM, 32/
1104) and are uncorrected. Reactions were monitored by thin
layer chromatography carried out using pre-coated silica gel
plates (E. Merck and Co., Darmstadt, Germany). UV studies
were carried out on a UV Visible spectrophotometer (Shima-
dzu 1700) and the kmax of the respective synthesised com-
pounds was determined using ethanol as the solvent. The IR
spectra (KBr) were recorded on a FTIR spectrophotometer
with Diffuse Reﬂectance attachment (Shimadzu 8400S). The
1H NMR spectra were obtained on an NMR Spectrophotom-
eter (Bruker Avance II 400 NMR) using dimethyl sulphoxide-
d6 as the solvent. Chemical shifts were expressed in parts
per million relative to SiMe4 as an internal standard. The
mass spectra were obtained on a Hewlett Packard Electron
Impact mass spectrometer GCD-1800A (70 eV EI source)
using a direct insertion probe and a Quadrapole TOF Mass
spectrometer using electrospray ionisation (Positive mode).
Microanalyses were performed on a Thermo Finnigan C, H,
N analyser.
2.2. Synthesis
2.2.1. General procedure for the synthesis of N0-[(1Z)-
(substituted aryl)methylidene] pyridine-4-carbohydrazides
(Schiff’s base)
The synthesis of compounds (3a–k) was performed according
to our previously reported procedure (Scheme 1) Thomas
et al., 2009. Isoniazid (0.01 M) and appropriate aromatic
aldehydes (0.01 M) (2a–k) in water were irradiated under
microwave using a microwave synthesiser (Make-Raga’s Sci-
entiﬁc, India) at power level 3 (240 W, 35% irradiation) in an
open vessel until the completion of the reaction. The reaction
was monitored by TLC (acetone/ethanol = 4:1). The reac-
tion mixture was then ﬁltered, the residue obtained was
washed with water, followed by sodium thiosulphate
(Na2S2O3) solution and dried. The crude product upon
recrystallisation from alcohol gave the pure hydrazones of
INH (3a–k). The synthesised compounds were characterised
on the basis of their spectral and analytical data. (UV, IR,
1H NMR, MS, CHN).
Scheme 1 Microwave assisted synthesis of intermediate Schiff’s
bases of INH (3a–k).
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carbohydrazide (3a). White crystals, yield 95.6, mp 262–
264 C, IR (mmax, cm1, KBr): 3344 (–OH), 3178 (–NH),
3004 (–CH), 1685 (amide C‚O), 1566 (imine C‚N). 1H
NMR (400 MHz, DMSO-d6): d ppm 11 (s, OH), 8.8–8.9 (d,
Pyridine 2H), 8.6–8.8 (d, Pyridine 2H), 8.7 (s, CH), 7.5–7.6
(d, Aromatic1H), 8.6 (s, NH), 6.8–7.0 (d, Aromatic 2H), 7.3–
7.4 (m, Aromatic1H). MS: m/z 242.5 (M+H)+. Anal. Calcd
for C13H11N3O2 (241.25): C, 64.72; H, 4.60; N, 17.42%.
Found: C, 64.51; H, 4.73; N, 17.60%.
2.2.1.2. N0-[(1Z)-(4-Hydroxyphenyl)methylidene]pyridine-4-
carbohydrazide (3b). Yellow powder, yield 94.5, mp 264–
268 C, IR (mmax, cm1, KBr): 3340 (–OH), 3213 (–NH),
3055 (–CH), 1662 (amide C‚O), 1608 (imine C‚N). 1H
NMR (400 MHz, DMSO-d6): d ppm 11.5 (s, OH), 8.8–8.5
(d, Pyridine 2H), 8.4–8.3 (d, Pyridine 2H), 7.8 (s, CH), 8.0
(s, NH) 7.5–7.3 (d, Aromatic 2H), 7.0–6.8 (d, Aromatic 2H).
MS: m/z 242.5(M+H)+. Anal. Calcd for C13H11N3O2
(241.25): C, 64.72; H, 4.60; N, 17.42%. Found: C, 64.57; H,
4.52; N, 17.36%.
2.2.1.3.N0-[(1Z)-(4-Chlorophenyl)methylidene]pyridine-4-car-
bohydrazide (3c). White crystals, yield 98.1, mp 218–221 C,
IR (mmax, cm
1, KBr): 3166 (–NH), 3020 (–CH), 1674 (amide
C‚O), 1593 (imine C‚N), 698 (–Cl). 1H NMR (400 MHz,
DMSO-d6): d ppm 8.88–8.91 (d, Pyridine 2H), 8.32 (s, CH),
8.65 (s, NH), 7.99–8.05 (d, Pyridine 2H), 7.79–7.80 (d, Aro-
matic 2H), 7.50–7.51 (d, Aromatic 2H). MS: m/z 260.4
(M+H)+. Anal. Calcd for C13H10ClN3O (259.69): C, 60.12;
H, 3.88; N, 16.18%. Found: C, 60.34; H, 3.76; N, 16.13%.
2.2.1.4. N0-[(1Z)-(4-Nitrophenyl)methylidene]pyridine-4-car-
bohydrazide (3d). Yellow powder, yield 90.7, mp 255–257 C,
IR (mmax, cm
1, KBr): 3186 (–NH), 3001 (–CH), 1685 (amide
C‚O), 1558 (imine C‚N), 1334, 1512 (–NO2).
1H NMR
(400 MHz, DMSO-d6): d ppm 9.32–9.35 (d, Pyridine 2H),
8.51–8.55 (d, Pyridine 2H), 8.34 (s, NH), 8.10 (s, CH), 7.89–
7.93 (d, Aromatic 2H), 7.60–7.62 (d, Aromatic 2H). MS: m/z
271.4 (M+H)+. Anal. Calcd for C13H10N4O3 (270.24): C,
57.78; H, 3.73; N, 20.73%. Found: C, 58.07; H, 3.68; N,
20.51%.
2.2.1.5. N0-[(1Z)-(2-Nitrophenyl) methylidene] pyridine-4-
carbohydrazide (3e). Orangish yellow powder, yield 99.2, mp
229–231 C, IR (mmax, cm1, KBr): 3193 (–NH), 3018 (–CH),
1677 (amide C‚O), 1552 (imine C‚N), 1517, 1363 (–NO2).
1H NMR (400 MHz, DMSO-d6): d ppm 9.04 (s CH), 8.77–
8.78 (d, Pyridine 2H), 8.62 (s, NH), 8.27–8.29 (d, Aromatic1H), 8.04–8.06 (d, Aromatic 1H), 7.88–7.89 (d, Pyridine 2H),
7.70–7.74 (m, Aromatic 1H), 7.59–7.63 (m, Aromatic 1H).
MS: m/z 271.5 (M+H)+. Anal. Calcd for C13H10N4O3
(270.24): C, 57.78; H, 3.73; N, 20.73%. Found: C, 57.92; H,
3.66; N, 20.95%.
2.2.1.6. N0-[(1Z)-(4-Flurophenyl)methylidene]pyridine-4-car-
bohydrazide (3f). White powder, yield 98.76, mp 189–190 C,
IR (mmax, cm
1, KBr): 3178 (–NH), 3064 (–CH), 1656 (amide
C‚O), 1598 (imine C‚N), 1301 (–F). 1H NMR (400 MHz,
DMSO-d6): d ppm 8.75–8.76 (d, Pyridine 2H), 8.46 (s, CH),
8.05 (s, NH), 7.83–7.84 (d, Pyridine 2H), 7.77–7.80 (d, Aro-
matic 2H), 7.08–7.10 (d, Aromatic2H). MS: m/z 245.4
(M+H)+. Anal. Calcd for C13H10FN3O (243.24): C, 64.19;
H, 4.14; N, 17.28%. Found: C, 64.83; H, 4.52; N, 18.02%.
2.2.1.7. N0-[(1Z)-(4-Methoxyphenyl)methylidene]pyridine-4-
carbohydrazide (3g). Off white powder, yield 90.98, mp 170–
173 C, IR (mmax, cm1, KBr): 3153 (–N–H), 3037 (–CH),
2995 (–CH), 1665 (–C‚O), 1600 (–C‚N), 1477 (–CH3).
1H
NMR (400 MHz, DMSO-d6): d ppm 8.75–8.85 (d, Pyridine
2H), 8.35 (s, –NH), 7.63–7.70 (d, Pyridine 2H, d, Aromatic
2H), 7.4 (s, ‚CH), 6.84–6.89 (d, Aromatic 2H), 3.78 (s, –
OCH3 3H). MS: m/z 256.5 (M+H)
+. Anal. Calcd for
C14H13N3O2 (255.27): C, 65.87; H, 5.13; N, 16.46%. Found:
C, 65.43; H, 5.64; N, 16.80%.
2.2.1.8. N0-[(1Z)-(4-Hydroxy-3-methoxyphenyl)methylidene]-
pyridine-4-carbohydrazide (3h). Yellow powder, yield 94.18,
mp 226–228 C, IR (mmax, cm1, KBr): 3517 (O–H), 3218
(–N–H), 3064 (–CH), 2985 (Alkane –CH), 1664 (–C‚O),
1568 (–N–H), 1596 (–C‚N), 1068 (‚C–O–C), 810, 881
(1,3,4-tri substituted alkene –CH). 1H NMR (400 MHz,
DMSO-d6): d ppm 9.48 (s, –NH), 9.37 (s, –OH), 8.74–8.75
(d, Pyridine 2H), 8.36 (s, ‚CH), 7.82–7.83 (d, Pyridine 2H),
7.37–7.38 (d, Aromatic 1H), 7.07–7.09 (d, Aromatic 1H),
6.64–6.68 (d, Aromatic 1H), 3.87 (s, –CH3). MS: m/z 272.4
(M+H)+. Anal. Calcd for C14H13N3O3 (271.27): C, 61.99;
H, 4.83; N, 15.49%. Found: C, 62.17; H, 4.92; N, 16.04%.
2.2.1.9. (Z)-N0-((Furan-2-yl)methylene)isonicotinohydrazide
(3i). Brownish powder, yield 92.09, mp 208–212 C, IR (mmax,
cm1, KBr): 3271 (–NH), 3051 (–CH), 1650 (amide C‚O),
1620 (imine C‚N), 1350 (C–O).1H NMR(400 MHz, DMSO-
d6): d ppm 8.91–8.89 (d, Pyridine 2H), 8.32 (s, NH),
8.18–8.13 (d, Pyridine 2H), 7.84 (s, CH), 7.54–7.52 (d, Furan
1H), 6.85–6.55 (m, Furan 2H), 5.97–5.92 (d, Furan 1H). MS:
m/z 216.4 (M+H)+. Anal. Calcd for C11H9N3O2 (215.21):
C, 61.39; H, 4.22; N, 19.53%. Found: C, 61.27; H, 4.13; N,
19.64%.
2.2.1.10. N0-{(1Z)-[4-(Dimethylamino)phenyl]methylidene}-
pyridine-4-carbohydrazide (3j). Yellow powder, yield 97.16,
mp 104–106 C, IR (mmax, cm1, KBr): 3153 (–N–H), 3045 (–
CH), 2961 (–CH), 1664 (–C‚O), 1604 (–C‚N). 1H NMR
(400 MHz, DMSO-d6): d ppm 8.73–8.72 (d, Pyridine 2H),
8.35 (s, ‚CH), 8.07 (s, –NH), 7.82–7.84 (d, Pyridine 2H),
7.62–7.60 (d, Aromatic 2H), 6.69–6.66 (d, Aromatic 2H),
3.07 (s, –CH3 6H). MS: m/z 269.5 (M+H)
+. Anal. Calcd
for C15H16N4O (268.31): C, 67.15; H, 6.01; N, 20.88%. Found:
C, 67.58; H, 6.12; N, 21.13%.
S82 A.B. Thomas et al.2.2.1.11. N0-[(1Z)-(2,5-Dimethoxyphenyl)methylidene]pyri-
dine-4-carbohydrazide (3k). Brown crystals, yield 95.2, mp
185–188 C, IR (mmax, cm1, KBr): 3190 (–NH), 3061 (–CH),
1654 (amide C‚O), 1600 (imine C‚N), 1060 (O–CH3).
1H
NMR (400 MHz, DMSO-d6): d ppm 8.89–8.92 (d, Pyridine
2H), 8.22 (s, CH), 8.48 (s, NH), 8.11–8.15 (d, Pyridine 2H),
7.5–7.8 (d of d, Aromatic 2H), 6.92 (s, Aromatic1H), 3.92–
4.12 (m, O–CH3). MS: m/z 286.5 (M+H)
+. Anal. Calcd for
C15H15N3O3 (285.3): C, 63.15; H, 5.30; N, 14.73%. Found:
C, 63.49; H, 5.21; N, 14.84%.
2.2.2. General procedure for synthesis of N-[3-chloro-2-(substituted
aryl)-4-oxoazetidin-1-yl] pyridine-4-carboxamide using Schiff’s
bases
The 2-azetidinones (5a–k) were synthesised as per our reported
methods of stirring and sonication (Thomas et al., 2010). To
the appropriate Schiff’s base (3a–k, 0.0025 M) dissolved in
dichloromethane, chloroacetyl chloride (0.0037 M), followed
by triethyl amine (0.0075 M) was added drop wise with con-
stant stirring at low temperature (0–5 C). The reaction was
carried out in the presence of molecular sieves [MS (1–2 g,
3A · 1.5 mm)]. The reaction mixture was further stirred at
room temperature until the completion of reaction. [TLC
(toulene/ethanol = 4.5:0.5)]. For the sonication method, the
reaction mixture was sonicated on an ultrasonic bath [Local
make] until the completion of reaction [TLC (toulene/etha-
nol = 4.5:0.5)], Scheme 2. The reaction mixture was added
into crushed ice and stirred to obtain the crude product. The
product obtained was washed with concentrated brine and
sodium bicarbonate solution and then dried. The crude prod-
uct on recrystallisation from alcohol yielded the pure 2-azetid-
inones of isonicotinoyl hydrazones (5a–k). The synthesised
compounds were characterised on the basis of their spectral
and analytical data (UV, IR, 1H NMR, MS, CNH).
2.2.2.1. N-[3-Chloro-2-(2-hydroxyphenyl)-4-oxoazetidin-1-yl]-
pyridine-4-carboxamide (5a). Yellow powder, yield 91.1, mpScheme 2 Synthesis of 2-azetidino98–101 C, IR (mmax, cm1, KBr): 3467 (–OH), 3193 (–NH),
3043 (–CH), 1774 (ring C‚O), 1677 (amide C‚O). 1H
NMR (400 MHz, DMSO-d6): d ppm 8.89–8.83 (d, Pyridine
2H), 8.22 (s, OH), 7.77–7.75 (d, Pyridine 2H), 7.36–7.38 (m,
Aromatic, 4H), 5.75–5.71 (d, CH Aze ring (C-3) 1H), 4.51–
4.42 (d, CH Aze ring (C-4), 4.91 (s, –NH). MS: m/z 318.4
(M+H)+. Anal. Calcd for C15H12ClN3O3 (317.73): C, 56.7;
H, 3.81; N, 13.23%. Found: C, 56.96; H, 3.92; N, 13.54%.
2.2.2.2. N-[3-Chloro-2-(4-hydroxyphenyl)-4-oxoazetidin-1-yl]
pyridine-4-carboxamide (5b). Yellow powder, yield 86, mp
102–105 C, IR (mmax, cm1, KBr): 3556 (–OH), 3186 (–NH),
3008 (–CH), 1766 (ring –C‚O), 1685 (amide –C‚O). 1H
NMR (400 MHz, DMSO-d6): d ppm 8.77–8.79 (d, Pyridine,
2H),8.31 (s, OH 1H), 7.96–7.93 (d, Pyridine, 2H), 7.24–7.23
(d, Aromatic, 2H), 6.86–6.84 (d, Aromatic, 2H), 5.71–5.68
(d, Aze ring H (C-3) 1H), 4.50 (s, NH Secondary amide 1H),
4.19–4.21 (d, CH Aze ring (C-4) 1H)). MS: m/z 318.5
(M+H)+. Anal. Calcd for C15H12ClN3O3 (317.73): C, 56.7;
H, 3.81; N, 13.23%. Found: C, 56.38; H, 3.97; N, 13.33%.
2.2.2.3. N-[3-Chloro-2-(4-chlorophenyl)-4-oxoazetidin-1-
yl]pyridine-4-carboxamide(5c). Brown crystals, yield 81.9,
mp 92–95 C, IR (mmax, cm1, KBr): 3193 (–NH), 3024 (–
CH), 1720 (ring C‚O), 1666 (amide C‚O), 829 (–Cl). 1H
NMR (400 MHz, DMSO-d6): d ppm 9.38–9.36 (d, Pyridine
2H), 8.30–8.28 (d, Pyridine 2H), 7.70–7.76 (d, Aromatic 2H),
7.35–7.33 (d, Aromatic 2H), 5.81–5.80 (d, CH Aze ring (C-3)
1H), 5.43–5.42 (d, CH Aze ring (C-4) 1H), 4.78 (s, –NH).
MS: m/z 337.5 (M+H)+. Anal. Calcd for C15H11Cl2N3O2
(336.17): C, 53.59; H, 3.30; N, 12.50%. Found: C, 53.87; H,
3.24; N, 12.34%.
2.2.2.4. N-[3-Chloro-2-(4-nitrophenyl)-4-oxoazetidin-1-yl]pyr-
idine-4-carboxamide (5d). Brown crystals, yield 85.8, mp 112–
116 C, IR (mmax, cm1, KBr): 3035 (–NH), 2974 (–CH), 1735
(ring C‚O), 1685 (amide C‚O), 1519, 1338 (–NO2).
1Hnes (5a–k) using Schiff’s bases.
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2H), 8.30–8.28 (d, Aromatic 2H), 7.97–7.95 (d, Pyridine 2H),
7.19–7.17 (d, Aromatic 2H), 5.81–5.80 (d, CH Aze ring (C-3)
1H), 5.43–5.42 (d, CH Aze ring (C-4), 1H), 4.91 (s, –NH).
MS: m/z 347.4 (M+H)+. Anal. Calcd for C15H11ClN4O4
(346.73): C, 51.96; H, 3.20; N, 16.16%. Found: C, 52.09; H,
3.13; N, 16.23%.
2.2.2.5. N-[3-Chloro-2-(2-nitrophenyl)-4-oxoazetidin-1-yl]pyr-
idine-4-carboxamide (5e). Pale yellow powder, yield 85.1, mp
193–194 C, IR (mmax, cm1, KBr): 3174 (NH), 3016 (CH),
1774 (ring –C‚O), 1697 (amide –C‚O), 1666 (NH), 1523,
1353 (NO2), 744 (CH).
1H NMR (400 MHz, DMSO-d6): d
ppm 9.07–9.08 (d, Pyridine, 2H), 8.81 (s, NH Secondary amide
1H), 8.32–8.28 (d, Aromatic 1H), 8.04–8.13 (m, Aromatic 1H),
7.99–8.00 (d, Pyridine 2H), 7.84–7.86 (d, Aromatic 1H), 7.60 –
7.74 (m, Aromatic 1H), 5.79, 5.85 (m, CH Aze ring (C-3) 1H),
5.42, 5.45 (d, CH Aze ring (C-4) 1H). MS: m/z 347.5(M+H)+.
Anal. Calcd for C15H11ClN4O4 (346.73): C, 51.96; H, 3.20; N,
16.16%. Found: C, 51.81; H, 3.12; N, 16.24%.
2.2.2.6 . N-[3-Chloro-2-(4-ﬂuorophenyl)-4-oxoazetidin-1-yl]-
pyridine-4-carboxamide (5f). Yellow powder, yield 95.2, mp
132–135 C, IR (mmax, cm1, KBr): 3182 (–NH), 3062 (–CH),
1789 (ring C‚O), 1662 (amide C‚O). 1H NMR (400 MHz,
DMSO-d6): d ppm8.52–8.51 (d, Pyridine 2H), 7.93–7.92 (d, Pyr-
idine 2H), 8.79 (s, –NH), 7.82–7.75 (m,Aromatic 2H), 7.02–7.05
(m, Aromatic 2H), 5.44, 5.43 (d, CH Aze ring (C-3) 1H),
4.99,5.01 (d, CH Aze ring (C-4) 1H). MS: m/z 320.5
(M+H)+. Anal. Calcd for C15H11ClFN3O2 (319.72): C,
56.35;H, 3.47;N, 13.14%.Found: C, 56.18;H, 3.38;N, 13.22%.
2.2.2.7. N-[3-Chloro-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]-
pyridine-4-carboxamide (5g). Pale yellow powder, yield 88.4,
mp 103–105, IR (mmax, cm
1, KBr): 3205 (–NH), 3047 (CH),
1770 (ring C‚O), 1666 (amide C‚O), 1604 (NH), 1253 (O–
CH3), 837 (CH).
1H NMR (400 MHz, DMSO-d6): d ppm
9.07–9.08 (d, Pyridine 2H), 8.87–8.90 (d, Pyridine 2H), 8.60
(s, NH Secondary amide 1H), 8.19–8.20 (d, Pyridine 2H),
7.70–7.72 (d, Aromatic 2H), 6.93–6.95 (d, Aromatic 2H),
5.74–5.75 (d, CH Aze ring (C-3) 1H), 5.04–5.06 (d, CH Aze
ring (C-4) 1H), 3.84 (s, OCH3 3H). MS: m/z 332.4
(M+H)+. Anal. Calcd for C16H14ClN3O3 (331.75): C, 57.93;
H, 4.25; N, 12.67%. Found: C, 58.12; H, 4.31; N, 12.55%.
2.2.2.8. N-[3-Chloro-2-(3-methoxy-4-hydroxyphenyl)-4-oxoaz-
etidin-1-yl]pyridine-4-carboxamide (5h). Brown crystals, yield
89.2, mp 134–135, IR (mmax, cm
1, KBr): 3444 (OH), 3180
(NH), 3010 (CH), 2972 (CH), 1789 (ring C‚O), 1660 (amide
C‚O), 1577 (NH), 1135 (O–CH3), 813, 844 (CH).
1H NMR
(400 MHz, DMSO-d6): d ppm 8.93–8.95 (d, Pyridine 2H),
8.76 (s, –NH Secondary amide 1H), 8.61 (s, Aromatic –OH
1H), 7.78–7.79 (d, Pyridine 2H), 7.42–6.87 (complex multiplet,
Aromatic 3H), 5.74–5.75 (d, CH Aze ring (C-3) 1H), 4.44–4.46
(d, CH Aze ring (C-4) 1H), 4.09 (s, O–CH3 3H). MS: m/z 348.4
(M+H)+. Anal. Calcd for C16H14ClN3O4 (347.75): C, 55.26;
H, 4.06; N, 12.08%. Found: C, 55.41; H, 4.17; N, 12.12%.
2.2.2.9. N-[3-Chloro-2-oxo-4-(tetrahydro-2H-pyran-3-yl)azeti-
din-1-yl]pyridine-4-carboxamide (5i). Pale brown powder,
yield 79.57, mp 174–179 C, IR (mmax, cm1, KBr): 3271 (–NH), 3051 (–CH), 1782 (ring C‚O), 1647 (amide C‚O). 1H
NMR (400 MHz, DMSO-d6): d ppm 8.48–8.47 (d, Pyridine
2H), 7.58–7.57 (d, Pyridine 2H), 7.99–7.97 (d, Furan ring
1H), 7.86–7.85 (m, Furan ring 1H), 6.53–6.52 (d, Furan ring
1H), 8.79 (s, –NH), 7.82–7.75 (m, Aromatic 2H), 7.02–7.05
(m, Aromatic 2H), 4.55–4.47 (d, CH Aze ring (C-3) 1H),
4.17–4.15 (d, CH Aze ring (C-4) 1H). MS: m/z 292.4
(M+H)+. Anal. Calcd for C13H10ClN3O3 (291.69): C, 53.35;
H, 3.46; N, 14.41%. Found: C, 53.58; H, 3.23; N, 14.54%.
2.2.2.10. N-[3-Chloro-2-(4-dimethylaminophenyl)-4-oxoazeti-
din-1-yl]pyridine-4-carboxamide (5j). Brown crystals, yield
87.32, mp 127–128 C, IR (mmax, cm1, KBr): 3190 (–NH),
3039 (–CH), 2891 (–CH), 1712 (ring C‚O), 1647 (amide
C‚O). 1H NMR (400 MHz, DMSO-d6): d ppm 8.79–8.78
(d, Pyridine 2H), 7.97–7.87 (d, Pyridine 2H), 8.44 (s, –NH),
7.68–7.67 (d, Aromatic 2H), 7.35–7.33 (d, Aromatic, 2H),
1H), 5.81–5.72 (d, CH Aze ring (C-3), 1H), 4.60–4.51 (d, CH
Aze ring (C-4), 3.09 (s, –CH3 6H). MS: m/z 345.5 (M+H)
+.
Anal. Calcd for C17H17ClN4O2 (344.8): C, 59.22; H, 4.97; N,
16.25%. Found: C, 59.57; H, 5.01; N, 16.32%.
2.2.2.11. N-[3-Chloro-2-(2,5-dimethoxyphenyl)-4-oxoazetidin-
1-yl]pyridine-4-carboxamide (5k). Pale brown crystals, yield
89.4, mp 140–148 C; IR (mmax, cm1, KBr): 3195 (–NH), 2974
(–CH), 1735 (ring C‚O), 1681 (amide C‚O), 1073 (O–CH3).
1H NMR (400 MHz, DMSO-d6): d ppm 9.38–9.36 (d, Pyridine
2H), 7.97–7.84 (d, Pyridine 2H), 4.42 (s, –NH), 6.83–6.86 (d,
Aromatic 1H), 6.19 (s, Aromatic 1H), 6.21 (d, Aromatic, 1H),
5.42–5.43 (d, CHAze ring (C-3), 1H), 4.78–4.90 (d, CHAze ring
(C-4), 1H), 3.77–3.60 (m,O–CH3 6H).MS:m/z 362.5 (M+H)
+.
Anal. Calcd for C17H16ClN3O4 (361.78): C, 56.44; H, 4.46; N,
11.61%. Found: C, 56.67; H, 4.33; N, 11.42%.3. Biological activity
3.1. Experimental animals
Swiss albino mice of either sex (20–30 g) were obtained from
the National Toxicological Centre (NTC), Pune; Serum Insti-
tute, Pune, India and were used for the biological studies. They
were housed under standard laboratory conditions, main-
tained on a natural dark and light cycle and had free access
to food and water. Animals were acclimatised to laboratory
conditions before the experimentation. All experiments were
carried out between 0900 and 1500 h. The screening protocol
was approved by the Institutional Ethics Committee and con-
ducted according to the Indian National Science Academy
Guidelines for the use and care of experimental animals (RP.
No. 048).
3.2. Acute toxicity study
The acute toxicity study for the test drugs was carried out in
mice according to OECD guidelines (OECD-423, 2004). Albi-
no mice of either sex weighing between 20 and 25 g were di-
vided into six groups of six animals each. Animals were
starved for 24 h with water ad libitum prior to test. On the
day of the experiment, test drugs were administered at graded
doses up to 2000 mg/kg, p.o. and animals were monitored indi-
vidually and continuously for 30 min, 2 h and up to 24 h to de-
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and also for tremors, convulsions, excessive salivation, diar-
rhoea, lethargy, sleep and coma. The animals were then mon-
itored for any mortality for the following 14 days. As there was
no toxic reaction or mortality observed, the test drugs were
found to be devoid of any toxicity up to a maximum dose of
2000 mg/kg body weight.3.3. Evaluation of nootropic activity
3.3.1. Elevated plus-maze test in mice
The effect of the test drugs on learning and memory was
investigated using transfer latency (TL) as the parameter for
the acquisition and retention of memory process in the
elevated plus-maze test in mice. An elevated plus maze consist-
ing of two open arms (16 · 5 cm) and two enclosed arms
(16 · 5 · 12 cm) elevated 25 cm from the ﬂoor was used in
the present study. Albino mice of either sex weighing between
20 and 25 g were divided into 24 groups of six animals each.
Animals were starved for 24 h with water ad libitum prior to
test. The animals were placed at the corner of an open arm fac-
ing away from the centre of maze and the time taken by each
animal to enter the closed arm was noted as transfer latency
(TL), on the 7th and 8th day after administering the test drugs
for continuous 7 days. The control group received 1 ml of
0.5% carboxy methyl cellulose (CMC) solution. The test com-
pounds 3a–k, 5a–k at two graded doses of 50 and 100 mg/kg
were administered orally in the form of suspension in 0.5%
CMC solution. Piracetam (400 mg/kg) was used as the stan-
dard drug and scopolamine (0.4 mg/kg) was employed as the
antagonist in the study.3.3.2. Passive avoidance test in mice
The nootropic activity was also evaluated using the Passive
Avoidance test in mice. Albino mice of either sex weighing be-
tween 20 and 25 g were divided into 24 groups of six animals
each. Animals were starved for 24 h with water ad libitum
prior to the experiment. A rectangular box (50 · 50 cm) with
electriﬁable grid ﬂoor and 35 cm ﬁts over the block was em-
ployed for the test. The grid ﬂoor was connected to a shock de-
vice which delivered scrambled foot shocks (50 Hz; 1.5 mA;
1 s). The step down latency times (SDL) were measured in
the training test and after 24 h in the retention test. The test
is ﬁnished when the mice steps down or remains on the plat-
form (cut-off time: 120 s) (Joshi and Parle, 2006).3.4. Evaluation of antidepressant activity
3.4.1. Forced swim test in mice
The antidepressant activity of test compounds was investigated
by the forced swim in mice. In the forced swim test, the mice
were individually forced to swim inside a vertical plexiglass cyl-
inder (height: 40 cm; diameter: 18 cm) containing 15 cm of
water maintained at 25 C. The mice placed in the cylinders
for the ﬁrst time were initially highly active, however after 2–
3 min the activity subsided and the phases of immobility in-
creased. After 5–6 min, the duration of immobility reached a
plateau where the mice remained immobile for about 80% ofthe time. After 15 min in the water, the rats were removed, al-
lowed to dry in a heated enclosure (32 C) and then returned to
their home cages. The total duration of immobility was mea-
sured during a 5 min test after the animals were placed in the
cylinder 24 h later.
3.4.2. Tail suspension test in mice
The antidepressant activity was also assessed by the Tail sus-
pension test in mice. Albino mice of either sex weighing be-
tween 20 and 25 g were suspended on the edge of a shelf
58 cm above a table top by an adhesive tape placed approxi-
mately 1 cm from the tip of the tail. The duration of immobil-
ity of each animal was recorded for a period of 5 min. The test
compounds 3a–k, 5a–k (50/100 mg/kg) were administered
orally in the form of a suspension in 0.5% CMC solution
and the standard Fluoxetine (10 mg/kg) intraperitoneally 1 h
before the performance of both tests (Zhang et al., 2001).
3.5. Statistical analysis
All values in the tests were expressed as means ± SEM for n
observations, where n represents number of animals studied
(n= 6). The data were analysed by ANOVA followed by
Dunnett’s test. In all the tests the criterion for statistical signif-
icance was p< 0.05 when compared with the control group.4. Results and discussion
4.1. Chemistry
The N0-[(1Z)-(substituted aromatic) methylidene] pyridine-4-
carbohydrazide (3a–k) were prepared in excellent yields in a
one-step reaction (Scheme 1) of isonocotinyl hydrazone (1)
with various substituted aryl aldehydes (2a–k) in water using
our previously reported microwave irradiation method. Isoni-
azid (INH, 0.01 M) and appropriate aromatic aldehydes
(0.01 M, 2a–k) in water on irradiation under microwave at
power level 3 (240 W, 35% irradiation) gave N0-[(1Z)-(substi-
tuted aromatic)methylidene] pyridine-4-carbohydrazide.
The conventional reaction for the synthesis of Schiff’s bases
of isonicotinic acid hydrazide involves the use of glacial acetic
acid as a catalyst with longer reaction times (360–420 min re-
ﬂux) for the completion of the reaction. In contrast, the micro-
wave method required shorter reaction times (7–9 min for
completion of reaction) with improved yields (90.7–98.76%).
The synthesised Schiff’s base intermediates (3a–k) were charac-
terised by the presence of strong band at 1552–1620 cm1 for
the N‚C imino group. The 1H NMR spectra also showed a
singlet signal equivalent to 1 proton for ‚CH group between
7.4 and 9.04 ppm, conﬁrming the formation of Schiff’s bases.
The synthesised intermediates were further utilised for the
synthesis of N-[3-chloro-2-(substituted aromatic)-4-oxoazeti-
din-1-yl]pyridine-4-carboxamides (5a–k) containing 2-azetidi-
none nucleus by our reported methods of stirring and
sonication (Scheme 2). The appropriate Schiff’s base (3a–k,
0.0025 M) in dichloromethane on reaction with chloroacetyl
chloride (4, 0.0037 M), followed by the addition of triethyl
amine (0.0075 M) in the presence of molecular sieves [MS (1–
2 g, 3A · 1.5 mm)] gave the 2-azetidinone derivatives in high
Synthesis and biological evaluation of Schiff’s bases and 2-azetidinones of isonocotinyl hydrazone S85yields (79.5–95.2%). The IR spectra of the synthesised deriva-
tives were characterised by the presence of a strong band at
1712–1789 cm1 for the ring carbonyl group, which is
considered a strong conﬁrmation for the azetidinone nucleus
formation. Another piece of evidence for cyclization is the
appearance of a doublet signal equivalent to 1 proton in 1H
NMR spectrum between 4.47 and 5.85 ppm (C-3, CH) and a
doublet signal equivalent to 1 proton between 4.17 and
5.45 ppm (C-4, CH), which represent the formation of azetidi-
none nucleus. The structures of the synthesised compounds
were further conﬁrmed by mass spectra and elemental analysis.Figure 1 Effect of 3a–k on transfer latency in elevated plus maze in
Figure 2 Effect of 5a–k on transfer latency in elevated plus maze in
*p< 0.05, **p< 0.01 when compared with vehicle treated control gro
Figure 3 Effect of 3a–k on transfer latency in elevate4.2. Biological activity
All the newly synthesised N0-[(1Z)-(substituted aromatic)meth-
ylidene] pyridine-4-carbohydrazide (3a–k) and their N-[3-
chloro-2-(substituted aromatic)-4-oxoazetidin-1-yl]pyridine-4-
carboxamide derivatives (5a–k) were tested in animal models
for their nootropic and antidepressant activities.
The nootropic activity was evaluated by the elevated plus
maze and passive avoidance tests in mice at two graded dose
levels of 50 mg/kg and 100 mg/kg. All the tested compounds
exhibited a signiﬁcant decrease (*p< 0.05) in the transfer la-mice. The transfer latency was compared to standard Piracetam.
mice. One way ANOVA followed by Dunnett test was employed,
up.
d plus maze in mice in scopolamine treated group.
S86 A.B. Thomas et al.tency (TL) on the eighth day indicating an improvement in the
cognitive function. All the tested drugs showed an increase in
the activity at the dose level of 100 mg/kg suggesting that the
activity is dose dependent. Of the entire newly synthesised
N0-[(1Z)-(substituted aromatic) methylidene]pyridine-4-carbo-Figure 4 Effect of 5a–k on transfer latency in elevated plus maze in
Dunnett test was employed; *p< 0.05, **p< 0.01 when compared wi
Figure 5 Effect of 3a–k on passive avoidance induced step down la
standard Piracetam.
Figure 6 Effects of 5a–k on passive avoidance induced step down l
carried out; *p< 0.05, **p< 0.01 when compared with vehicle treatedhydrazides, the compound 3d with an electron withdrawing ni-
tro substitution at the para position of the aryl ring exhibited
the highest activity (TL period: 23.3 s). Compounds 3c, 3e, 3h,
and 3k with 4-Cl; 2-NO2; 4-OH, 3-OCH3; and 2,5-dimethoxy
substitution on the aryl ring also exhibited signiﬁcant activitymice (Scopolamine treated group). One way ANOVA followed by
th vehicle treated control group.
tency in mice. The step down latency period was compared with
atency in mice. One way ANOVA followed by Dunnett test was
control group.
Synthesis and biological evaluation of Schiff’s bases and 2-azetidinones of isonocotinyl hydrazone S87comparable to 3d (TL period: 25.2, 25.1, 24.6, 25.2 s, respec-
tively). However all the tested compounds showed lower activ-
ity as compared to the standard drug Piracetam (TL period:
14.0 s at 400 mg/kg). Among the N-[3-chloro-2-(substituted
aromatic)-4-oxoazetidin-1-yl]pyridine-4-carboxamide deriva-Figure 8 Effects of 5a–k on passive avoidance induced step down lat
followed by Dunnett test was carried out; *p< 0.05, **p< 0.01 when
Figure 7 Effect of 3a–k on passive avoidance induced step down late
with standard Piracetam and antagonist Scopolamine.
Figure 9 Effect of 3a–k on tail suspension-induced immobility in mitives synthesised, compound 4d with the similar p-nitrophenyl
ring substituted at C-4 position of the azetidinone ring exhib-
ited the highest activity (TL period: 22.4 s). Furthermore com-
pounds 4e and 4h also showed activity comparable to 4d.
Although, the 2-azetidinones synthesised in the present studyency in mice in the Scopolamine treated group. One way ANOVA
compared with vehicle treated control group.
ncy in mice in scopolamine treated group. Results were compared
ce. Duration of immobility was compared to standard ﬂuoxetine .
Figure 10 Effect of 5a–k on tail suspension induced immobility in mice. The duration of immobility is compared with standard
Fluoxetine. One way ANOVA followed by Dunnett test was carried out; *p< 0.05, **p< 0.01 when compared with vehicle treated
control group.
Figure 11 Effect of 3a–k on duration of immobility in forced swim test in mice. Duration of immobility was compared to standard
Fluoxetine. 0.5% CMC acts as the vehicle control.
Figure 12 Effect of 5a–k on duration of immobility in forced swim test in mice. Duration of immobility was compared to standard
Fluoxetine. One way ANOVA followed by Dunnett test was carried out; *p< 0.05, **p< 0.01 when compared with vehicle treated
control group.
S88 A.B. Thomas et al.did not exhibit substantial activity as compared to piracetam,
there has been an enhancement in the nootropic activity (Figs.
1 and 2).In the scopolamine treated group (Figs. 3 and 4), an in-
crease in the transfer latency period was observed. However,
all the tested compounds were able to competitively inhibit
Synthesis and biological evaluation of Schiff’s bases and 2-azetidinones of isonocotinyl hydrazone S89the antagonistic action of scopolamine. It was observed that
the synthesised 2-azetidinones were able to more effectively
show a reversal of the scopolamine-induced memory deﬁcit
as compared to the intermediate Schiff’s bases.
In the passive avoidance test for the evaluation of nootropic
activity, all the tested compounds exhibited a signiﬁcant in-
crease (*p< 0.05) in the step down latency period on the
eighth day indicating improvement in the cognitive function.
The compounds 3c, 3d, 3e, 3h and 4c, 4d, 4e and 4h exhibited
signiﬁcant activity in concordance to the elevated plus maze
test (Figs. 5–8). The results suggest an indirect evidence of
the participation of cholinergic and NMDA-receptor block-
ades in the mechanism of these drugs.
The antidepressant activity data in both the tail suspen-
sion (Figs. 9 and 10) and forced swim test (Figs. 11 and
12) in mice indicated that all the synthesised Schiff’s base
(3a–k) and 2-azetidinone analogues (5a–k) exhibited signiﬁ-
cant activity (*p< 0.05). Anti-depressants activity was ob-
served in a dose dependant manner, showing increased
activity at 100 mg/kg dose level. Compounds 3k and 4k with
2,5-dimethoxy substitution on the aryl ring exhibited the
highest antidepressant activity (duration of immobility:77.1,
65.6 s, respectively) as compared to the nitro substituted
derivative in the cognitive models and similar to the standard
Fluoxetine (79.6 s). Compounds 3c, 3d, 3e, 3h; 4c, 4d, 4e, 4h
with 4-Cl, 4-NO2; 2-NO2; 4-OH, 3-OCH3 substitutions on the
aryl ring also exhibited signiﬁcant activity (duration of immo-
bility: 88.5, 84.1, 78.0, 83.0 s; 73.6, 71.8, 67.1, 68.5 s, respec-
tively) comparable to 3k and 4k. Surprisingly, the 2-
azetidinone analogues exhibited a substantial enhancement
in activity when compared to the synthesised intermediates.
The behavioural response of individual rats to forced swim-
ming can be correlated with changes in extracellular 5-HT
in the lateral septum.
The results of the cognitive models for evaluation of the
nootropic activity and the antidepressant testing indicate that
the nature of the substituent, i.e., their electronic parameters
and their position on the 2-azetidinone nucleus might play a
signiﬁcant role in inﬂuencing the in vivo activity.5. Conclusions
In the present study, the synthesis and CNS activity of 2-aze-
tidinone derivatives have been described. The synthesis of
the N0-[(1Z)-(substituted aromatic) methylidene]pyridine-4-
carbohydrazides and N-[3-chloro-2-(substituted aromatic)-4-
oxoazetidin-1-yl]pyridine-4-carboxamides were carried out by
us using a new green route method of microwave irradiation
and stirring/sonication resulting in improved yield with shorter
reaction times. It was observed that the tested compounds con-
taining electron withdrawing (nitro, halogen and dimethoxy)
moiety on phenyl ring of Schiff’s bases and 2-azetidinones
were found to have signiﬁcant invivo nootropic and antide-
pressant activities in the animal models. These results conﬁrm
the fact that the 2-azetidinone skeleton has potential as a CNS
active agent. In conclusion, it can be stated that the 2-azetidi-
nones deserve further investigation to gain insight into the
mechanistic action of the most active compounds to help in
the development of more potent and safe CNS active agents
for therapeutic use.Acknowledgements
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